Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary. Objectives: To describe the ...

Medicare Part D may cover Basaglar, a long-acting insulin, and under the Inflation Reduction Act, the cost should not exceed $35 per month. The availability of Basaglar under Medicare Part D depends ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand-name ...